---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-009799"
form_type: "8-K"
ticker: "SYRA"
cik: "0001922335"
company_name: "Syra Health Corp"
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:54:55.060491+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Syra Health FY2025 net loss down 76%; Population Health revenue up 157% to $5.3M

## Summary
- FY2025 revenue $7.2M (-9% YoY); net loss improved 76% to ($896K) from ($3.8M).
- EPS improved to ($0.08) from ($0.50) in FY2024; Q4 2025 net loss ($135K) vs ($504K) Q4 2024.
- Population Health revenue grew 157% to $5.3M; gross margin expanded to 34.4% from 20.7%.
- Operating expenses down 37% to $3.4M; adjusted EBITDA improved to ($863K) from ($3.7M).
- Company expects profitability by year-end 2026; cash $1.6M, no long-term debt.

## SEC filing metadata
- accession: 0001493152-26-009799
- form_type: 8-K
- ticker: SYRA
- cik: 0001922335
- company_name: Syra Health Corp
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1922335/000149315226009799/0001493152-26-009799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1922335/000149315226009799/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-009799
- JSON: https://secwatch.observer/filing/0001493152-26-009799.json
- Plain text: https://secwatch.observer/filing/0001493152-26-009799.txt

## Key facts
- Earnings Releases
  Syra Health Corp reported Q4 2025 results: net income ($135K), EPS ($0.01).
  - Period: Q4 2025
  - Net income: ($135K)
  - EPS: ($0.01)
  - Result: reported results
  source text: Q4 and Full Year 2025 Financial Highlights ● Population Health revenue grew 157% year-over-year to $5.3 million in FY2025 from $2.1 million in FY2024, driven by demand for the Company's higher margin yielding population health solutions, including data analytics, health education and training. Q4 2025 Population Health revenue grew 128% year-over-year to $1.3 million, compared to $550K in Q4 2024. ● Earnings per share improved by $0.42 in FY2025 to ($0.08) from ($0.50) in FY2024. Q4 2025 EPS improved to ($0.01) from ($0.08) in Q42024, representing meaningful progress as the Company moves closer to profitability. ● Total operating expenses declined 37% to $3.4 million in FY2025 when compared to $5.4 million in FY2024. Q4 2025 operating expenses decreased 13% to $727K from $836K in Q4 2024. ● Net loss improved 76% to ($896K) in FY2025 from ($3.8M) in FY2024. Q4 2025 net loss was reduced 73% to ($135K) versus ($504K) in Q4 2024, reflecting a significantly improved cost structure. ● Gross
  evidence_url: https://www.sec.gov/Archives/edgar/data/1922335/000149315226009799/0001493152-26-009799-index.htm
- Earnings Releases
  Syra Health Corp updated its FY2026 guidance (initiated).
  - Period: FY2026
  - Guidance: initiated
  - Result: guidance update
  source text: 2026 Financial Outlook ● The Company expects to achieve profitability by year-end 2026, driven by continued strong demand for its comprehensive population health solutions, disciplined cost management, and new contract wins.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1922335/000149315226009799/0001493152-26-009799-index.htm
- Earnings Releases
  Syra Health Corp reported FY2025 results: revenue $7,225,973, net income ($896,333), EPS ($0.08).
  - Period: FY2025
  - Revenue: $7,225,973
  - Net income: ($896,333)
  - EPS: ($0.08)
  - Result: reported results
  source text: Syra Health Corp Statements of Operations For the Years Ended December 31, 2025 and 2024 December revenues $ 7,225,973 $ 7,982,082 Cost of services 4,738,211 6,329,119 Gross profit 2,487,762 1,652,963 OPERATING EXPENSES: Salaries and benefits 1,500,688 2,718,743 Professional services 737,714 606,051 Research and development expenses 67,840 585,146 Selling, general and administrative expenses 1,065,376 1,445,170 Depreciation 20,468 62,738 Total operating expenses 3,392,086 5,417,848 Net loss from operations (904,324 ) (3,764,885 ) OTHER INCOME (EXPENSES): Interest income 21,261 21,247 Interest expense (13,270 ) (15,600 ) Total other income (expense) 7,991 5,647 NET INCOME (LOSS) $ (896,333 ) $ (3,759,238 ) Loss per common share, basic and diluted $ (0.08 ) $ (0.50 ) Weighted average number of common shares outstanding, basic and diluted 11,852,347 7,551,576
  evidence_url: https://www.sec.gov/Archives/edgar/data/1922335/000149315226009799/0001493152-26-009799-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.